FR2453644A1 - Solutions medicamenteuses stables applicables par voie parenterale, contenant, a titre de principes actifs, un derive de l'acide arylacetique ou arylpropionique avec des phospholipides ainsi que leur preparation - Google Patents

Solutions medicamenteuses stables applicables par voie parenterale, contenant, a titre de principes actifs, un derive de l'acide arylacetique ou arylpropionique avec des phospholipides ainsi que leur preparation

Info

Publication number
FR2453644A1
FR2453644A1 FR8007937A FR8007937A FR2453644A1 FR 2453644 A1 FR2453644 A1 FR 2453644A1 FR 8007937 A FR8007937 A FR 8007937A FR 8007937 A FR8007937 A FR 8007937A FR 2453644 A1 FR2453644 A1 FR 2453644A1
Authority
FR
France
Prior art keywords
phospholipids
derivative
preparation
arylacetic
parentally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8007937A
Other languages
English (en)
Other versions
FR2453644B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Publication of FR2453644A1 publication Critical patent/FR2453644A1/fr
Application granted granted Critical
Publication of FR2453644B1 publication Critical patent/FR2453644B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

SOLUTIONS MEDICAMENTEUSES STABLES APPLICABLES PAR VOIE PARENTERALE, A EFFET D'INHIBITION DE L'INFLAMMATION, AINSI QUE LEUR PREPARATION. L'INVENTION CONCERNE EN PARTICULIER DES SOLUTIONS MEDICAMENTEUSES STABLES, APPLICABLES PAR VOIE PARENTERALE, CARACTERISEES EN CE QU'ELLES CONTIENNENT UN COMPLEXE SOLUBLE DANS L'EAU CONSTITUE D'UN DERIVE, ACTIF COMME INHIBITEUR DE L'INFLAMMATION, DE L'ACIDE ARYLACETIQUE OU DE L'ACIDE ARYLPROPIONIQUE AVEC DES PHOSPHOLIPIDES. APPLICATION A L'INDUSTRIE PHARMACEUTIQUE.
FR8007937A 1979-04-11 1980-04-09 Solutions medicamenteuses stables applicables par voie parenterale, contenant, a titre de principes actifs, un derive de l'acide arylacetique ou arylpropionique avec des phospholipides ainsi que leur preparation Expired FR2453644B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792914788 DE2914788A1 (de) 1979-04-11 1979-04-11 Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung

Publications (2)

Publication Number Publication Date
FR2453644A1 true FR2453644A1 (fr) 1980-11-07
FR2453644B1 FR2453644B1 (fr) 1985-07-05

Family

ID=6068137

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8007937A Expired FR2453644B1 (fr) 1979-04-11 1980-04-09 Solutions medicamenteuses stables applicables par voie parenterale, contenant, a titre de principes actifs, un derive de l'acide arylacetique ou arylpropionique avec des phospholipides ainsi que leur preparation

Country Status (14)

Country Link
US (1) US4309421A (fr)
JP (1) JPS55141407A (fr)
AT (1) AT369651B (fr)
AU (1) AU539044B2 (fr)
BE (1) BE882731A (fr)
CA (1) CA1144480A (fr)
CH (1) CH642546A5 (fr)
DE (1) DE2914788A1 (fr)
FR (1) FR2453644B1 (fr)
GB (1) GB2046094B (fr)
IT (1) IT1148790B (fr)
NL (1) NL8002097A (fr)
SE (1) SE451427B (fr)
ZA (1) ZA802157B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051833A1 (fr) * 1980-11-10 1982-05-19 Extrakta Strauss GmbH Systèmes mono-phasiques liquides à plusieurs substances contenant de la lécithine

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203011A (en) * 1981-06-05 1982-12-13 Taiyo Yakuhin Kogyo Kk Anti-inflammatory external agent
EP0146243A1 (fr) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Inhibiteurs de la lipoxygénase
DE3346526C2 (de) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
DE3346525A1 (de) * 1983-12-22 1985-07-04 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US5171566A (en) * 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
DE3621036A1 (de) * 1986-06-24 1988-01-07 Merckle Gmbh Fluessige ibuprofen-zubereitungen
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
CH673395A5 (fr) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
CA1319886C (fr) * 1987-02-03 1993-07-06 Alberto Ferro Solutions de micelles mixtes
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DE4124252A1 (de) * 1991-07-22 1993-01-28 Knoll Ag Verfahren zur herstellung einer sterilfiltrierbaren wirkstoffloesung
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
DE4305003A1 (de) * 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
DE69621773T2 (de) * 1995-01-27 2003-01-02 Univ Texas Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen
EP0855906B1 (fr) * 1995-10-17 2008-02-20 Jagotec AG Administration de medicaments insolubles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
CN1289091C (zh) * 1998-02-11 2006-12-13 Rtp药品公司 治疗炎症的药物组合物和相关用途
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DK1079808T3 (da) 1998-05-29 2004-06-07 Skyepharma Canada Inc Præparater med termisk beskyttede mikropartikler og fremgangsmåde til slutdampsterilisering deraf
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
CA2338703C (fr) 1998-08-19 2009-03-24 Rtp Pharma Inc. Dispersions aqueuses injectables de propofol
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
CA2407027C (fr) 2000-04-20 2011-02-15 Rtp Pharma Inc. Procede ameliore destine aux particules de medicament insolubles dans l'eau
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
CA2420597C (fr) 2000-08-31 2011-05-17 Rtp Pharma Inc. Particules broyees
NZ525231A (en) * 2000-09-20 2004-08-27 Skyepharma Canada Inc Phospholipid stabilised feno-fibrate microparticles for pharmaceutical use
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
CA2440355C (fr) * 2001-02-22 2011-03-08 Skyepharma Canada Inc. Combinaisons statine et fibrate presentant des effets secondaires alimentaires indesirables a jeun-nourri reduits
US20040132823A1 (en) * 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
CN1852721B (zh) * 2003-07-31 2013-03-27 得克萨斯大学体系董事会 用于治疗、预防和/或改善癌症、癌症发病或癌症症状的组合物和方法
MX2008010101A (es) * 2006-02-06 2009-02-27 Pharmaceutical Solutions Inc Preparaciones antiinflamatorias no esteroides orales líquidas y en polvo para administración en animales.
CA2658314A1 (fr) * 2006-07-26 2008-01-31 The Board Of Regents Of The University Of Texas System Preparations parenterale d'anti-inflammatoires associes a des phospholipides a toxicite gi reduite, et procedes de preparation de d'utilisation de celles-ci
ES2694506T3 (es) 2009-03-12 2018-12-21 Cumberland Pharmaceuticals Inc. Administración de ibuprofeno por vía intravenosa
US20110028556A1 (en) * 2009-07-31 2011-02-03 Cumberland Pharmaceuticals, Inc. Treating critically ill patients with intravenous ibuprofen
US8735452B2 (en) * 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
FR2971712B1 (fr) * 2011-02-22 2016-06-10 Map France Solution stable de ketoprofene pour injection intraveineuse
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
US9072661B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
PE20150083A1 (es) 2012-03-16 2015-01-21 Cumberland Pharmaceuticals Inc Formulacion de ibuprofeno inyectable
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
ES2955693T3 (es) 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3044931A (en) * 1960-01-27 1962-07-17 Geigy Chem Corp Aryloxy acetic acid amides: process for parenteral application
DE2712031A1 (de) * 1976-03-19 1977-09-29 Ici Ltd Pharmazeutische zusammensetzung mit einem gehalt an liposomen
FR2445146A1 (fr) * 1978-12-27 1980-07-25 Nattermann A & Cie Medicament a prise orale contenant une substance inhibitrice de l'inflammation et un ou plusieurs phospholipides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) * 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
JPS6320209A (ja) * 1986-07-11 1988-01-27 Mitsubishi Motors Corp 油圧サスペンシヨン装置を備える車両の車高調整方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3044931A (en) * 1960-01-27 1962-07-17 Geigy Chem Corp Aryloxy acetic acid amides: process for parenteral application
DE2712031A1 (de) * 1976-03-19 1977-09-29 Ici Ltd Pharmazeutische zusammensetzung mit einem gehalt an liposomen
FR2445146A1 (fr) * 1978-12-27 1980-07-25 Nattermann A & Cie Medicament a prise orale contenant une substance inhibitrice de l'inflammation et un ou plusieurs phospholipides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051833A1 (fr) * 1980-11-10 1982-05-19 Extrakta Strauss GmbH Systèmes mono-phasiques liquides à plusieurs substances contenant de la lécithine

Also Published As

Publication number Publication date
ATA195880A (de) 1982-06-15
FR2453644B1 (fr) 1985-07-05
AU5733180A (en) 1980-10-16
SE8002714L (sv) 1980-10-12
IT8021299A0 (it) 1980-04-10
US4309421A (en) 1982-01-05
CA1144480A (fr) 1983-04-12
JPS55141407A (en) 1980-11-05
SE451427B (sv) 1987-10-12
NL8002097A (nl) 1980-10-14
GB2046094B (en) 1983-10-26
GB2046094A (en) 1980-11-12
CH642546A5 (de) 1984-04-30
JPH0337524B2 (fr) 1991-06-05
IT1148790B (it) 1986-12-03
ZA802157B (en) 1981-05-27
DE2914788A1 (de) 1980-10-16
AT369651B (de) 1983-01-25
AU539044B2 (en) 1984-09-06
DE2914788C2 (fr) 1990-06-21
BE882731A (fr) 1980-07-31

Similar Documents

Publication Publication Date Title
FR2453644A1 (fr) Solutions medicamenteuses stables applicables par voie parenterale, contenant, a titre de principes actifs, un derive de l'acide arylacetique ou arylpropionique avec des phospholipides ainsi que leur preparation
RU92004423A (ru) Препарат из растений curcuma
FR2356424A1 (fr) Compositions pharmaceutiques a base d'acide phophono-formique utiles pour lutter contre les infections virales
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
FR2635265B1 (fr) Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation
GT198900008A (es) Derivados de quinolina, quinazolina y cinolina.
JPS63104931A (ja) 酸化に対して安定化された薬剤組成物
TNSN98059A1 (fr) Composes inhibiteurs selectifs de cox-2, anti-inflammatoires et compositions pharmaceutiques les contenant.
FR2453649A1 (fr) Composition pharmaceutique a action prolongee contenant des acides biliaires utile notamment pour la lyse des calculs
FR2698788B1 (fr) Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
FR2453650A1 (fr) Medicament a base de derives du cholecalciferol, utilisable pour regler le metabolisme des os chez les homeothermes
PL308142A1 (en) Derivatives of 2-amino-4phenyl-4-oxobutyric acids as kynureninase and/or kynurenic 3-hydroxylase inhibitors
FR2453646A1 (fr) Medicaments anti-inflammatoires injectables a base d'un complexe d'un derive d'acide indole- ou indane-acetique et de phospholipide, ainsi que leur preparation
FR2354761A1 (fr) Acides n-aryl-anthraniliques, leurs procedes de preparation et compositions pharmaceutiques contenant lesdits acides anthraniliques
ITMI930582A1 (it) Composizione farmeceutiche ad attivita' analgesica
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
FR2712809B1 (fr) Nouvelle composition pharmaceutique destinée à la préparation d'une poudre stable contenant, à titre d'ingrédient actif, une association d'acide acétylsalicylique et de métoclopramide.
TNSN98088A1 (fr) INHIBITEURS DE FARNESYL- TRANSFERASE EN ASSOCIATION AVEC DES INHIBITEURS DE HMG-CoA-REDUCTASE POUR LE TRAITEMENT DU CANCER.
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
IL82523A0 (en) Microbicidal compositions,their manufacture and drugs containing them
FR2421173A1 (fr) 2-(4-ethylpiperazino)-4-phenylquinoleine et ses sels, utiles notamment comme antidepresseurs, et leur procede de preparation
FR2408591A1 (fr) 4-aroyl-4-hydroxypiperidines substituees en position 1, leurs sels d'addition avec des acides, utilisables comme medicaments antipsychotiques
ES8205394A1 (es) Procedimiento para preparar esteres de l-arginina en solu- cion acuosa
FR2380778A1 (fr) Compositions pharmaceutiques contenant des acides oxaniliques substitues ou leurs esters

Legal Events

Date Code Title Description
ST Notification of lapse